Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer
Yuankai Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Nan Ge(China Medical University), Jian Feng(National University of Defense Technology), Gongyan Chen(Harbin Medical University), Ying Cheng(Jilin Province Tumor Hospital), Aimin Zang, Lin Wu(Materials Systems (United States)), Yong Jiang(The First People's Hospital of Changzhou), Yuping Li(Guangdong Province Women and Children Hospital), Xiang Wang(Central South University), Chunling Liu(Xinjiang Medical University), Shucai Zhang(Northeastern University), Hui Zhao(Dalian Medical University), Jiwei Liu(Mongolian University of Science and Technology), Shuyang Zhu(Xuzhou Medical College), Jiuwei Cui(Jilin University), Xiaodong Zhang(Shanghai Jiao Tong University), Yunpeng Liu(Shenyang Institute of Automation), Lejie Cao(University of Science and Technology of China), Fei Liu(Cangzhou Central Hospital), Jie Hu(Brigham and Women's Hospital), Nong Yang(Central South University), Yanrong Hao(The People's Hospital of Guangxi Zhuang Autonomous Region)
Cited by 7
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k